Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a report released on Thursday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

Shares of SENS opened at $0.35 on Thursday. The company’s fifty day moving average is $0.36 and its 200-day moving average is $0.41. Senseonics has a 12 month low of $0.32 and a 12 month high of $0.75. The firm has a market cap of $184.99 million, a price-to-earnings ratio of -2.66 and a beta of 0.79. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. Equities analysts expect that Senseonics will post -0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after purchasing an additional 155,715 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Senseonics by 30.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after acquiring an additional 211,128 shares during the period. Symmetry Partners LLC bought a new stake in shares of Senseonics in the third quarter valued at about $164,000. Cubist Systematic Strategies LLC boosted its position in shares of Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.